Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 68475-42-3
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of anagrelide during breastfeeding. The manufacturer recommends that the drug not be used during breastfeeding and for 1 week after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
anagrelide
CAS Registry Number
68475-42-3
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Effects of anagrelide on platelet cAMP levels, cAMP-dependent protein kinase and thrombin-induced Ca++ fluxes.[J Pharmacol Exp Ther. 1987]Effects of anagrelide on platelet cAMP levels, cAMP-dependent protein kinase and thrombin-induced Ca++ fluxes.Seiler S, Arnold AJ, Grove RI, Fifer CA, Keely SL Jr, Stanton HC. J Pharmacol Exp Ther. 1987 Nov; 243(2):767-74.
- Review AbobotulinumtoxinA.[Drugs and Lactation Database (...]Review AbobotulinumtoxinA.. Drugs and Lactation Database (LactMed®). 2006
- Disposition of anagrelide, an inhibitor of platelet aggregation.[Clin Pharmacol Ther. 1981]Disposition of anagrelide, an inhibitor of platelet aggregation.Gaver RC, Deeb G, Pittman KA, Smyth RD. Clin Pharmacol Ther. 1981 Mar; 29(3):381-6.
- Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures.[Br J Pharmacol. 2005]Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures.Wang G, Franklin R, Hong Y, Erusalimsky JD. Br J Pharmacol. 2005 Oct; 146(3):324-32.
- Review Temozolamide.[Drugs and Lactation Database (...]Review Temozolamide.. Drugs and Lactation Database (LactMed®). 2006
- Anagrelide - Drugs and Lactation Database (LactMed®)Anagrelide - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...